CN113661177B - EGFR x CD28多特异性抗体 - Google Patents

EGFR x CD28多特异性抗体 Download PDF

Info

Publication number
CN113661177B
CN113661177B CN202080022975.8A CN202080022975A CN113661177B CN 113661177 B CN113661177 B CN 113661177B CN 202080022975 A CN202080022975 A CN 202080022975A CN 113661177 B CN113661177 B CN 113661177B
Authority
CN
China
Prior art keywords
antigen binding
seq
egfr
binding domain
bispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080022975.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113661177A (zh
Inventor
D·思科科斯
A·J·墨菲
G·D·扬科普洛斯
L·哈伯
林家杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN113661177A publication Critical patent/CN113661177A/zh
Application granted granted Critical
Publication of CN113661177B publication Critical patent/CN113661177B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202080022975.8A 2019-03-22 2020-03-20 EGFR x CD28多特异性抗体 Active CN113661177B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962822124P 2019-03-22 2019-03-22
US62/822,124 2019-03-22
PCT/US2020/023857 WO2020198009A1 (en) 2019-03-22 2020-03-20 EGFR x CD28 MULTISPECIFIC ANTIBODIES

Publications (2)

Publication Number Publication Date
CN113661177A CN113661177A (zh) 2021-11-16
CN113661177B true CN113661177B (zh) 2024-04-16

Family

ID=70228885

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080022975.8A Active CN113661177B (zh) 2019-03-22 2020-03-20 EGFR x CD28多特异性抗体

Country Status (18)

Country Link
US (2) US11912767B2 (enExample)
EP (1) EP3941941A1 (enExample)
JP (2) JP7659501B2 (enExample)
KR (1) KR20210142659A (enExample)
CN (1) CN113661177B (enExample)
AU (1) AU2020247803A1 (enExample)
BR (1) BR112021018442A2 (enExample)
CA (1) CA3134335A1 (enExample)
CL (2) CL2021002446A1 (enExample)
CO (1) CO2021014076A2 (enExample)
EA (1) EA202192566A1 (enExample)
IL (1) IL286536A (enExample)
MA (1) MA55363A (enExample)
MX (1) MX2021011500A (enExample)
MY (1) MY209363A (enExample)
PH (1) PH12021552300A1 (enExample)
SG (1) SG11202110341WA (enExample)
WO (1) WO2020198009A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3810282A1 (en) * 2018-06-21 2021-04-28 Regeneron Pharmaceuticals, Inc. Bispecific anti-psma x anti-cd28 antibodies and uses thereof
JP7659501B2 (ja) 2019-03-22 2025-04-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ＥＧＦＲｘＣＤ２８多特異性抗体
KR20230166150A (ko) 2020-08-19 2023-12-06 젠코어 인코포레이티드 항-cd28 조성물
MX2023005081A (es) * 2020-10-30 2023-06-15 Janux Therapeutics Inc Anticuerpos multiespecificos para dirigirse a cd28 y pd-l1 y metodos de uso de los mismos.
EP4240762A1 (en) * 2020-11-03 2023-09-13 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
EP4274901A1 (en) 2021-01-11 2023-11-15 Sana Biotechnology, Inc. Use of cd8-targeted viral vectors
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
JP2024528981A (ja) 2021-08-04 2024-08-01 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ４標的化ウイルスベクターの使用
EP4472646A1 (en) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023164510A1 (en) 2022-02-23 2023-08-31 Xencor, Inc. Anti-cd28 x anti-psma antibodies
JP2025508066A (ja) 2022-03-07 2025-03-21 ノビミューン エスアー 目的としたｔ細胞活性化のためのｃｄ２８二重特異性抗体
WO2023174925A1 (en) 2022-03-14 2023-09-21 Novimmune Sa Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
CN118922449A (zh) * 2022-04-11 2024-11-08 江苏恒瑞医药股份有限公司 特异性结合psma和cd28的抗原结合分子及其医药用途
CN119013295A (zh) * 2022-04-11 2024-11-22 江苏恒瑞医药股份有限公司 特异性结合egfr和cd28的抗原结合分子及其医药用途
WO2024015418A1 (en) 2022-07-13 2024-01-18 Regeneron Pharmaceuticals, Inc. Mild acid immunoassays for detection of analytes
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
JP2025533075A (ja) * 2022-10-03 2025-10-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性ＥＧＦＲｘＣＤ２８抗体単独又は抗ＰＤ－１抗体との併用による癌治療方法
EP4605421A1 (en) 2022-10-21 2025-08-27 Novimmune S.A. Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
WO2024237744A1 (ko) * 2023-05-18 2024-11-21 서울대학교산학협력단 항-cd40l/항-cd28 이중 특이 항체 및 이의 용도
WO2025014913A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Bispecific pd-l1xcd28 antibodies and methods of use thereof
WO2025026356A1 (zh) * 2023-07-31 2025-02-06 百奥泰生物制药股份有限公司 靶向肿瘤相关抗原与cd28的双特异性抗体及其应用
CN120647771A (zh) * 2024-03-15 2025-09-16 上海鑫湾生物科技有限公司 一种激活免疫细胞杀伤肿瘤细胞的融合蛋白及其重组病毒和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104411722A (zh) * 2012-06-25 2015-03-11 瑞泽恩制药公司 抗egfr抗体及其使用
CN104558190A (zh) * 2015-01-06 2015-04-29 中国药科大学 一种全人源靶向EGFR/KDR的IgG样双特异性抗体
CN106632681A (zh) * 2016-10-11 2017-05-10 北京东方百泰生物科技有限公司 抗egfr 和抗cd3双特异抗体及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
WO2007042261A2 (en) 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
NZ573557A (en) 2006-06-02 2010-08-27 Regeneron Pharma High affinity antibodies to human il-6 receptor
DK2505654T4 (da) 2010-02-08 2020-07-27 Regeneron Pharma Mus med fælles letkæde
BR112014015018A2 (pt) 2011-12-19 2020-10-27 Synimmune Gmbh moléculas de anticorpo biespecífico e seu método de produção, bem como composição farmacêutica e molécula de ácido nucleico
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
AU2016325630B2 (en) 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
MY199468A (en) 2016-09-23 2023-10-31 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
PT3515946T (pt) 2016-09-23 2022-08-04 Regeneron Pharma Anticorpos anti-muc16 (mucin 16)
BR112021010238A2 (pt) * 2018-12-19 2021-08-24 Regeneron Pharmaceuticals, Inc. Anticorpos anti-cd28 x anti-cd22 biespecíficos e usos dos mesmos
JP7659501B2 (ja) 2019-03-22 2025-04-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ＥＧＦＲｘＣＤ２８多特異性抗体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104411722A (zh) * 2012-06-25 2015-03-11 瑞泽恩制药公司 抗egfr抗体及其使用
CN104558190A (zh) * 2015-01-06 2015-04-29 中国药科大学 一种全人源靶向EGFR/KDR的IgG样双特异性抗体
CN106632681A (zh) * 2016-10-11 2017-05-10 北京东方百泰生物科技有限公司 抗egfr 和抗cd3双特异抗体及其应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ t-cell activation and therapeutic efficacy;Jung G等;Int J Cancer;第91卷(第02期);第225-230页 *
Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: a pre-clinical study;Pfosser A等;Int J Cancer;第80卷(第04期);第612-616页 *
双特异性抗体及其在肿瘤诊治上的研究进展;李康等;医学分子生物学杂志(第03期);第233-235页 *
抗EGFR/CD3双特异性抗体的制备与功能的初步研究;车耀健等;福建医科大学学报;第51卷(第06期);第369-374页 *

Also Published As

Publication number Publication date
US11912767B2 (en) 2024-02-27
CL2023002805A1 (es) 2024-03-15
IL286536A (en) 2021-10-31
US12415856B2 (en) 2025-09-16
JP7659501B2 (ja) 2025-04-09
SG11202110341WA (en) 2021-10-28
JP2022526764A (ja) 2022-05-26
EA202192566A1 (ru) 2021-12-27
CN113661177A (zh) 2021-11-16
US20200299388A1 (en) 2020-09-24
CL2021002446A1 (es) 2022-05-06
JP2024160318A (ja) 2024-11-13
EP3941941A1 (en) 2022-01-26
MX2021011500A (es) 2021-10-22
BR112021018442A2 (pt) 2022-01-11
KR20210142659A (ko) 2021-11-25
MA55363A (fr) 2022-01-26
WO2020198009A8 (en) 2020-11-19
AU2020247803A1 (en) 2021-11-11
CA3134335A1 (en) 2020-10-01
MY209363A (en) 2025-07-03
CO2021014076A2 (es) 2021-10-29
PH12021552300A1 (en) 2022-07-04
WO2020198009A1 (en) 2020-10-01
US20230322927A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
CN113661177B (zh) EGFR x CD28多特异性抗体
JP7170691B2 (ja) 抗ｌａｇ３抗体およびその使用
JP7174009B2 (ja) Ｐｄ－１に対するヒト抗体
JP2022025130A (ja) 抗ｐｓｍａ抗体、ｐｓｍａ及びｃｄ３と結合する二重特異性抗原結合分子、ならびにその使用
JP7034068B2 (ja) レプチン受容体を活性化させる抗原結合タンパク質
JP2015227381A (ja) ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体
JP2016519650A (ja) ヒト抗ｇｒｅｍ１抗体
JP7431750B2 (ja) カンナビノイド受容体１型（ｃｂ１）結合性タンパク質及びその使用
US20180208656A1 (en) Anti-Prokineticin Receptor (PROKR) Antibodies and Uses Thereof
US20250043017A1 (en) BISPECIFIC PD-L1x4-1BB ANTIBODIES AND METHODS OF USE THEREOF
US20250043002A1 (en) BISPECIFIC PD-L1xCD28 ANTIBODIES AND METHODS OF USE THEREOF
EA048356B1 (ru) МУЛЬТИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К EGFRxCD28

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant